Plasma-aminothiols status and inverse correlation of total homocysteine with B-vitamins in arsenic exposed population of West Bengal, India

Natural Dietary Compounds in the Treatment of Arsenic Toxicity

Chronic exposure to arsenic (As) compounds leads to its accumulation in the body, with skin lesions and cancer being the most typical outcomes. Treating As-induced diseases continues to be challenging as there is no specific, safe, and efficacious therapeutic management. Therapeutic and preventive measures available to combat As toxicity refer to chelation therapy, antioxidant therapy, and the intake of natural dietary compounds. Although chelation therapy is the most commonly used method for detoxifying As, it has several side effects resulting in various toxicities such as hepatotoxicity, neurotoxicity, and other adverse consequences. Drugs of plant origin and natural dietary compounds show efficient and progressive relief from As-mediated toxicity without any particular side effects. These natural compounds have also been found to aid the elimination of As from the body and, therefore, can be more effective than conventional therapeutic agents in ameliorating As toxicity. This review provides an overview of the recently updated knowledge on treating As poisoning through natural dietary compounds. This updated information may serve as a basis for defining novel prophylactic and therapeutic formulations.

Association of low blood arsenic exposure with level of malondialdehyde among Chinese adults aged 65 and older

High environmental arsenic exposure can increase chronic oxidative stress in experimental studies and in occupational epidemiology studies. Many regulatory agencies have put forth arsenic exposure limits, it is still unclear that whether low environmental arsenic exposure was associated with adverse health outcome in general population. This study aimed to explore the association of low blood arsenic with malondialdehyde in community-dwelling older adults. We used a cross-sectional study of 2384 older adult individuals aged ≥65 years (mean age: 85 years) from the Healthy Aging and Biomarkers Cohort Study in 2017. The median blood arsenic level was 1.41 μg/L. High oxidative stress was categorized according to the 95th percentile of MDA levels (7.47 nmol/mL). Restricted cubic spline models showed that blood arsenic levels were positively associated with malondialdehyde levels (P < 0.01); and the risk of high oxidative stress was no longer significantly increased when blood arsenic level up to 8.74 μg/L. After adjusting for potential confounders, the odds ratios of high oxidative stress for the second, third, and fourth quartiles of blood arsenic were 2.35 (1.11-4.96), 3.87 (1.90-7.91), and 4.18 (2.00-8.72) (P_trend < 0.01), compared with the first quartile. We concluded that even low arsenic exposure was associated with higher risk of oxidative stress, in a nonlinear dose-response.

A Systematic Review of the Various Effect of Arsenic on Glutathione Synthesis In Vitro and In Vivo

Background

Arsenic is a toxic metalloid widely present in nature, and arsenic poisoning in drinking water is a serious global public problem. Glutathione is an important reducing agent that inhibits arsenic-induced oxidative stress and participates in arsenic methylation metabolism. Therefore, glutathione plays an important role in regulating arsenic toxicity. In recent years, a large number of studies have shown that arsenic can regulate glutathione synthesis in many ways, but there are many contradictions in the research results. At present, the mechanism of the effect of arsenic on glutathione synthesis has not been elucidated.

Objective

We will conduct a meta-analysis to illustrate the effects of arsenic on GSH synthesis precursors Glu, Cys, Gly, and rate-limiting enzyme γ-GCS in mammalian models, as well as the regulation of p38/Nrf2 of γ-GCS subunit GCLC, and further explore the molecular mechanism of arsenic affecting glutathione synthesis.

Results

This meta-analysis included 30 studies in vivo and 58 studies in vitro, among which in vivo studies showed that arsenic exposure could reduce the contents of GSH (SMD = -2.86, 95% CI (-4.45, -1.27)), Glu (SMD = -1.11, 95% CI (-2.20,-0.02)), and Cys (SMD = -1.48, 95% CI (-2.63, -0.33)), with no statistically significant difference in p38/Nrf2, GCLC, and GCLM. In vitro studies showed that arsenic exposure increased intracellular GSH content (SMD = 1.87, 95% CI (0.18, 3.56)) and promoted the expression of p-p38 (SMD = 4.19, 95% CI (2.34, 6.05)), Nrf2 (SMD = 4.60, 95% CI (2.34, 6.86)), and GCLC (SMD = 1.32, 95% CI (0.23, 2.41)); the p38 inhibitor inhibited the expression of Nrf2 (SMD = -1.27, 95% CI (-2.46, -0.09)) and GCLC (SMD = -5.37, 95% CI (-5.37, -2.20)); siNrf2 inhibited the expression of GCLC, and BSO inhibited the synthesis of GSH. There is a dose-dependent relationship between the effects of exposure on GSH in vitro. Conclusions. These indicate the difference between in vivo and in vitro studies of the effect of arsenic on glutathione synthesis. In vivo studies have shown that arsenic exposure can reduce glutamate and cysteine levels and inhibit glutathione synthesis, while in vitro studies have shown that chronic low-dose arsenic exposure can activate the p38/Nrf2 pathway, upregulate GCLC expression, and promote glutathione synthesis.

What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors

In India, an unexplained enteropathy is present in a majority of non-cirrhotic intrahepatic portal hypertension (NCIPH) patients. Small intestinal bacterial contamination and tropical enteropathy could trigger inflammatory stimuli and activate the endothelium in the portal venous system. Groundwater contaminated with arsenic is an environmental factor of epidemic proportions in large areas of India which has similar consequences. Von Willebrand factor (a sticky protein) expressed by activated endothelium may promote formation of platelet microthrombi and occlusion of intrahepatic portal vein branches leading to NCIPH. Environmental factors linked to suboptimal hygiene and sanitation, which enter through the gastrointestinal (GI) tract, predispose to platelet plugging onto activated endothelium in portal microcirculation. Thus, NCIPH, an example of poverty linked thrombophilia, is a disease mainly affecting the lower socio-economic strata of Indian population. Public health measures to improve sanitation, provide clean drinking water and eliminate arsenic contamination of drinking water are urgently needed. Till such time as these environmental factors are addressed, NCIPH is likely to remain 'an Indian disease'.

Serum folate and cobalamin levels and urinary dimethylarsinic acid in US children and adults

Nutritional status could affect arsenic metabolism and toxicity in the general population chronically exposed to low levels of inorganic arsenic. In this study, we examined the association of serum folate and cobalamin with urinary concentrations of dimethylarsinic acid (DMA), the most abundant metabolite of inorganic arsenic measured in urine, in children and adults who participated in the 2003-2006 US National Health and Nutrition Examination Surveys. A total of 1161 children (aged 6-19 years) and 1938 adults (aged 20-85 years) were analyzed for the association using multivariate general linear models, adjusting for potential confounders. We observed a positive association between serum levels of folate and cobalamin and creatinine-corrected urinary concentrations of DMA in both children and adults. Furthermore, serum levels of folate and cobalamin were inversely associated with homocysteine (Hcy). These results suggest that dietary intake of folate and cobalamin may exhibit protective functions against arsenic toxicity by increasing arsenic metabolism to the less toxic metabolite DMA and decreasing serum levels of Hcy.

Nutritional management can assist a significant role in alleviation of arsenicosis

Consumption of arsenic contaminated water causes serious skin disease and cancer in a significant number of exposed people. Chelating agents, consider an expensive therapy, are employed in the treatment of arsenic intoxication. There are reports which suggest that the poorest suffer the most from arsenicosis. This may be due to improper diet intake, consist of low protein and micronutrients which increase the vulnerability to arsenic-related disorders. Several human studies demonstrated the associations between malnourishment and the development of arsenic-caused skin lesions, skin cancer and cardiovascular effects. Thus, there is an urgent need of implementation of mitigation strategies for improving the health of exposed populations. Nutrition enhances the detoxification process so food rich in vitamins, protein, antioxidants help in its detoxification process. Methylation is the detoxification process which takes place via S-adenosylmethionine (SAM). It is a methyl group donor and it derived its methyl group from diet. Nutritional intervention thus may appear as a practical and inexpensive approach. Nutrition provides protection from toxic effect of arsenic by two ways (i) methylation of As (ii) antioxidants which provides protection against free radical species. The governments and NGOs may run awareness programmes in arsenic affected area regarding prevention and alternate therapy which can decrease the susceptibility of the exposed population. They could also help in distributing cheaper, high protein diets particularly to the masses who cannot afford such foods. Thus, to prevent arsenicosis alternate therapy and proper nutrition could be the important strategy for alleviating its toxic effects. This mini review provides an insight on the importance of nutrition in preventing adverse effect cause by arsenic to suffer population.